Sonelokimab clinical trials
Also written M1095.
How each study uses sonelokimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the sonelokimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2024 (5)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2018 | 1 |
| 2022 | 2 |
| 2024 | 5 |
| 2025 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 0
MoonLake Immunotherapeutics AG (10) · Bond Avillion 2 Development LP (1) · Merck KGaA, Darmstadt, Germany (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test sonelokimab, phase 3 first.
- Jan 2027Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate ResponsePhase 3 · MoonLake Immunotherapeutics AG
Studies
Open first, then newest update. How each study uses sonelokimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic ArthritisEnrolling by invitationPhase 3MoonLake Immunotherapeutics AGNCT07223138Written as Sonelokimab
- A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis SuppurativaEnrolling by invitationPhase 3MoonLake Immunotherapeutics AGNCT07007637Written as Sonelokimab
- Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate ResponseActive, not recruitingPhase 3MoonLake Immunotherapeutics AGNCT06641089Written as Sonelokimab
- Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic DrugActive, not recruitingPhase 3MoonLake Immunotherapeutics AGNCT06641076Written as Sonelokimab
- An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)CompletedPhase 3MoonLake Immunotherapeutics AGNCT06768671Written as Sonelokimab
- Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic ArthritisCompletedPhase 2MoonLake Immunotherapeutics AGNCT05640245Written as Sonelokimab
- Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis SuppurativaCompletedPhase 2MoonLake Immunotherapeutics AGNCT05322473Written as Sonelokimab (M1095)
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis SuppurativaCompletedPhase 3MoonLake Immunotherapeutics AGNCT06411899Written as Sonelokimab
- Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis SuppurativaCompletedPhase 3MoonLake Immunotherapeutics AGNCT06411379Written as Sonelokimab
- An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence of a Single-dose Administration of Sonelokimab Either by a Prefilled Syringe or an AutoinjectorCompletedPhase 1MoonLake Immunotherapeutics AGNCT06994936Written as Sonelokimab
- A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe PsoriasisCompletedPhase 2Bond Avillion 2 Development LPNCT03384745Written as M1095 (Sonelokimab)
- Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis SubjectsCompletedPhase 1Merck KGaA, Darmstadt, GermanyNCT02156466Written as MSB0010841
Codes
What other systems call sonelokimab · ClinicalTrials.gg INT001785
- MeSH (NLM) C000720946sonelokimabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) LEN0OCZ4SHSONELOKIMABConfirmed FDA, NLM
- NCI Thesaurus C171838SonelokimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000720946 | sonelokimab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | LEN0OCZ4SH | SONELOKIMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C171838 | Sonelokimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.